These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 24930432

  • 21. Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle.
    Moreira C, Ferreira MRA, da Cunha CEP, Donassolo RA, Finger PF, Moreira GMSG, Otaka DY, de Sousa LA, Barbosa JD, Moreira ÂN, Salvarani FM, Conceição FR.
    Toxins (Basel); 2018 Sep 20; 10(10):. PubMed ID: 30241350
    [Abstract] [Full Text] [Related]

  • 22. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
    Zhou Y, Singh BR.
    Protein Expr Purif; 2004 Mar 20; 34(1):8-16. PubMed ID: 14766296
    [Abstract] [Full Text] [Related]

  • 23. High level expression and immunochemical characterization of botulinum neurotoxin type F light chain.
    Chauhan R, Chauhan V, Rao MK, Chaudhary D, Bhagyawant S, Dhaked RK.
    Protein Expr Purif; 2018 Jun 20; 146():51-60. PubMed ID: 29407166
    [Abstract] [Full Text] [Related]

  • 24. Development of immunodetection system for botulinum neurotoxin serotype E.
    Sarita R, Ponmariappan S, Sharma A, Kamboj DV, Jain AK.
    Indian J Med Res; 2018 Jun 20; 147(6):603-610. PubMed ID: 30168493
    [Abstract] [Full Text] [Related]

  • 25. Camelid-derived heavy-chain nanobody against Clostridium botulinum neurotoxin E in Pichia pastoris.
    Baghban R, Gargari SL, Rajabibazl M, Nazarian S, Bakherad H.
    Biotechnol Appl Biochem; 2016 Jun 20; 63(2):200-5. PubMed ID: 24673401
    [Abstract] [Full Text] [Related]

  • 26. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.
    Yu Y, Yu J, Li N, Wang S, Yu W, Sun Z.
    Vaccine; 2009 Oct 19; 27(44):6148-53. PubMed ID: 19712769
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Production of serotype C specific and serotype C/D generic monoclonal antibodies using recombinant H(C) and H(N) fragments from Clostridium botulinum neurotoxin types C(1) and D.
    Curran RM, Fringuelli E, Graham D, Elliott CT.
    Vet Immunol Immunopathol; 2009 Jul 15; 130(1-2):1-10. PubMed ID: 19233482
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
    Gao YL, Gao S, Kang L, Nie C, Wang JL.
    Hum Vaccin; 2010 Jun 15; 6(6):462-6. PubMed ID: 20519939
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Evaluation of long-term immune response in cattle to botulism using a recombinant E. coli bacterin formulated with Montanide™ ISA 50 and aluminum hydroxide adjuvants.
    Moreira C, Rodrigues RR, da Cunha CEP, Donassolo RA, Ferreira MRA, Finger PF, Oliveira HGS, da Cruz KP, Moreira ÂN, Salvarani FM, Conceição FR.
    Microb Pathog; 2024 Apr 15; 189():106596. PubMed ID: 38395317
    [Abstract] [Full Text] [Related]

  • 34. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ, Guo JP, An HJ, Zhang SM, Wang S, Yu WY, Sun ZW.
    Vaccine; 2013 May 07; 31(20):2427-32. PubMed ID: 23583890
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters.
    Jathoul AP, Holley JL, Garmory HS.
    Vaccine; 2004 Sep 28; 22(29-30):3942-6. PubMed ID: 15364442
    [Abstract] [Full Text] [Related]

  • 36. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
    Shi DY, Lu JS, Mao YY, Liu FJ, Wang R, Du P, Yu S, Yu YZ, Yang ZX.
    Appl Microbiol Biotechnol; 2023 May 28; 107(10):3205-3216. PubMed ID: 37058230
    [Abstract] [Full Text] [Related]

  • 37. Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.
    Villaflores OB, Hsei CM, Teng CY, Chen YJ, Wey JJ, Tsui PY, Shyu RH, Tung KL, Yeh JM, Chiao DJ, Wu TY.
    J Virol Methods; 2013 Apr 28; 189(1):58-64. PubMed ID: 23313783
    [Abstract] [Full Text] [Related]

  • 38. Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502.
    Fredrick CM, Lin G, Johnson EA.
    Appl Environ Microbiol; 2017 Jul 01; 83(13):. PubMed ID: 28455330
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
    Shi DY, Liu FJ, Mao YY, Cui RT, Lu JS, Yu YZ, Dong XJ, Yang ZX, Sun ZW, Pang XB.
    Hum Vaccin Immunother; 2020 Jul 01; 16(1):100-108. PubMed ID: 31210561
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.